Ascendis Pharma A/S (ASND) News Today → The biggest energy story ever? (From Porter & Company) (Ad) Free ASND Stock Alerts $141.01 +2.57 (+1.86%) (As of 05/1/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAscendis Pharma A/S (NASDAQ:ASND) Sees Large Growth in Short Interestamericanbankingnews.com - May 2 at 5:30 AMAscendis Pharma (spons ADRs) earnings preview: what to expectmarkets.businessinsider.com - May 1 at 10:51 AMAscendis Pharma A/S (NASDAQ:ASND) Short Interest Up 7.5% in Aprilmarketbeat.com - April 30 at 3:37 PMDevelopment dedicated to bioscience, pharma moves forward in Arlingtonmsn.com - April 29 at 10:13 PMEuropean Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Tradingmsn.com - April 29 at 12:12 PMLooking Into Ascendis Pharma's Recent Short Interestbenzinga.com - April 26 at 12:51 PMAscendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024globenewswire.com - April 25 at 4:46 PMabrdn plc Invests $17.48 Million in Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - April 25 at 6:14 AMUnited Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidismmarkets.businessinsider.com - April 24 at 10:24 AMAscendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic Hypoparathyroidismmarkets.businessinsider.com - April 24 at 10:24 AMUnited Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidismglobenewswire.com - April 24 at 8:30 AMAscendis Pharma A/S (ASND) Set to Announce Quarterly Earnings on Thursdaymarketbeat.com - April 24 at 6:45 AMAscendis Pharma A/S's (ASND) Equal Weight Rating Reaffirmed at Morgan Stanleyamericanbankingnews.com - April 23 at 3:18 AMAscendis Pharma A/S (NASDAQ:ASND) Rating Reiterated by Morgan Stanleymarketbeat.com - April 22 at 1:31 PMAscendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgeraldmarketbeat.com - April 18 at 10:28 AMSequoia Financial Advisors LLC Makes New $732,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - April 16 at 5:35 AMRaymond James Financial Services Advisors Inc. Has $1.04 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - April 15 at 4:27 AMAscendis Pharma A/S (NASDAQ:ASND) Sees Significant Increase in Short Interestmarketbeat.com - April 14 at 1:27 PMAscendis Pharma A/S (NASDAQ:ASND) Stock Position Reduced by Allspring Global Investments Holdings LLCmarketbeat.com - April 14 at 5:37 AMAscendis Pharma's Options Frenzy: What You Need to Knowbenzinga.com - April 12 at 2:11 PMAscendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 9 at 4:56 AMWeek In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billionseekingalpha.com - April 7 at 7:52 AMHere's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Yearsbenzinga.com - April 4 at 12:42 AMRoivant announces $1.5B share buyback, positive Phase 2 datamsn.com - April 2 at 1:38 PMBiotech With 520% Sales Growth Nears Next Buy Pointfinance.yahoo.com - April 2 at 1:38 PMJPMorgan Chase & Co. Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $167.00marketbeat.com - April 2 at 11:15 AMAscendis Pharma A/S's (ASND) "Overweight" Rating Reiterated at Cantor Fitzgeraldmarketbeat.com - April 1 at 9:10 AMAre Medical Stocks Lagging AdaptHealth (AHCO) This Year?finance.yahoo.com - March 22 at 8:25 PMTwo Health Care Stocks Outperform S&P 500, Offer Entriesfinance.yahoo.com - March 22 at 8:25 PMAscendis Pharma A/S (ASND) Rose on Positive Trial Resultsfinance.yahoo.com - March 22 at 8:22 AMWells Fargo & Company Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $260.00marketbeat.com - March 18 at 6:53 PMAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)markets.businessinsider.com - March 15 at 12:52 PMBuy Rating Affirmed for Ascendis Pharma Amid Favorable Market Dynamics and Strong TransCon PTH Outlookmarkets.businessinsider.com - March 15 at 12:52 PMAurobindo Pharma restarts aseptic product distribution; shares trade highermsn.com - March 14 at 9:21 PMSei Investments Co. Reduces Position in Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - March 8 at 8:05 AMAscendis Pharma A/S (ASND) Faced R&D Setbacks in Q4finance.yahoo.com - March 7 at 1:08 PMAscendis Pharma A/S (NASDAQ:ASND) is RA Capital Management L.P.'s Largest Positionmarketbeat.com - March 6 at 2:34 PMAdage Capital Partners GP L.L.C. Decreases Holdings in Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - March 5 at 1:20 PMAscendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024globenewswire.com - March 4 at 8:30 AMAscendis Pharma A/S ADRmorningstar.com - February 27 at 3:51 PMAscendis Pharma A/S (NASDAQ:ASND) is Westfield Capital Management Co. LP's 4th Largest Positionmarketbeat.com - February 26 at 11:32 AMAscendis Pharma A/S (NASDAQ:ASND) Hits New 12-Month High at $161.00marketbeat.com - February 26 at 10:51 AM$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Todaybenzinga.com - February 25 at 8:04 PMTimesSquare Capital Management LLC Buys 75,374 Shares of Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - February 25 at 11:54 AMAscendis Pharma A/S - ADRmoney.usnews.com - February 22 at 7:52 PMCenterBook Partners LP Has $892,000 Stake in Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - February 21 at 8:38 AMAscendis Pharma A/S (NASDAQ:ASND) Reaches New 52-Week High at $156.84marketbeat.com - February 20 at 10:38 AMFmr LLC Sells 4,523 Shares of Ascendis Pharma A/S (NASDAQ:ASND)marketbeat.com - February 20 at 7:31 AMAscendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Moderate Buy" by Brokeragesmarketbeat.com - February 19 at 3:41 AMAscendis Pharma A/S (NASDAQ:ASND) Stock Position Trimmed by Baillie Gifford & Co.marketbeat.com - February 17 at 9:19 AM Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s last act as President (Ad)You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. ASND Media Mentions By Week ASND Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.450.33▲Average Medical News Sentiment ASND News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼84▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LEGN News Today CERE News Today VKTX News Today ROIV News Today JAZZ News Today ITCI News Today ELAN News Today CYTK News Today IONS News Today CTLT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
